Mechanism
Tesamorelin is a stabilized synthetic analog of human growth-hormone-releasing hormone. Rather than supplying growth hormone directly, it prompts the pituitary to release it in a more natural pulsatile pattern — which raises IGF-1 and shifts fat metabolism.
| Mechanism | Detail |
|---|---|
| GHRH receptor agonism | Activates GHRH receptors on pituitary somatotrophs, stimulating synthesis and release of endogenous growth hormone. |
| Stabilized backbone | A modification to the native GHRH sequence slows enzymatic breakdown and extends half-life compared with unmodified GHRH. |
| IGF-1 elevation | Increased GH signaling raises circulating IGF-1 — the downstream mediator, and the marker clinicians monitor for over-response. |
| Preferential visceral lipolysis | Growth hormone promotes breakdown of visceral (intra-abdominal) fat in particular, the mechanism behind the reductions seen in trials. |
Evidence Summary
Tesamorelin is unusual: its core indication rests on large, double-blind, placebo-controlled Phase 3 trials, not anecdote. The strength of evidence drops sharply once you move outside that approved use.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Visceral fat (HIV lipodystrophy) | ~15–18% reduction vs placebo | Phase 3 RCT | Basis of FDA approval. Effect reverses after stopping. |
| Liver fat / NAFLD (in HIV) | Reduced hepatic fat, less fibrosis progression | RCT | Rigorous, but confined to the HIV population. |
| IGF-1 / GH axis | Consistently raises IGF-1 | RCT (biomarker) | Confirms mechanism; also the signal monitored for overexposure. |
| Cognition / brain aging | Small early signal | Small RCT | Not replicated at scale; hypothesis-generating. |
| Body composition / anti-aging | No dedicated healthy-adult trials | Extrapolation | The dominant reason it is sought; least supported by direct evidence. |
| Long-term safety (off-label) | Trial data ~1 year, HIV population | Evidence gap | Long-term use in otherwise-healthy people is not characterized. |
| Human clinical trials | Multiple placebo-controlled Phase 3 | Phase 3 RCT | A genuinely strong human base by peptide standards — for the approved indication. |
Divergence — What This Means
Strong data for one use; off-label everywhere else.
Clinically, tesamorelin is a well-validated drug for excess visceral abdominal fat in people with HIV-associated lipodystrophy, at a defined dose, under monitoring. In the community it is used far more broadly — general fat loss, body recomposition, “GH optimization,” anti-aging — none of which has been tested in dedicated trials.
The mechanism is real and the approved-use data are strong, so divergence is about population and purpose rather than whether it does anything. The sharper risk is sourcing: the approved product (Egrifta) is a manufactured pharmaceutical, while compounded or gray-market material varies in identity, purity, and dose.
The mechanism is real and the approved-use data are strong, so divergence is about population and purpose rather than whether it does anything. The sharper risk is sourcing: the approved product (Egrifta) is a manufactured pharmaceutical, while compounded or gray-market material varies in identity, purity, and dose.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Approved label dose
2 mg
subcutaneous, once daily
Route
Subcutaneous
rotating abdominal sites
Onset
Weeks to months
visceral fat measured over ~26 weeks in trials
Monitoring
IGF-1 & glucose
followed via bloodwork under a clinician
The 2 mg daily figure reflects the FDA-approved label for HIV-associated lipodystrophy. Reference information, not medical advice — tesamorelin is a prescription drug whose use and monitoring belong with a qualified clinician.
Safety Profile
Because tesamorelin has been through formal trials, its adverse-effect profile is better characterized than most peptides. Effects largely trace to elevated growth hormone and IGF-1.
Animal / preclinical — signals observed
Injection-site reactions (redness, itching, pain)
Arthralgia and myalgia (joint and muscle aches)
Fluid retention — peripheral edema, occasionally carpal-tunnel-type symptoms
Glucose effects — increases in blood sugar and HbA1c
Elevated IGF-1, sometimes above normal range, prompting dose review
What is not known (human)
Long-term safety in healthy, non-HIV adults using it off-label
Whether sustained IGF-1 elevation carries growth-signaling or malignancy risk over years
Effects during pregnancy and breastfeeding (contraindicated/not established)
Quality and dose accuracy of compounded or gray-market material
The approved label carries contraindications including active malignancy, disruption of the pituitary axis, and pregnancy. Educational summary, not a substitute for the prescribing information or medical advice.
Regulatory Status — Updated July 2026
An approved drug, not a compounding question
Tesamorelin is an FDA-approved prescription medication, marketed as Egrifta for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. As an approved drug, it was not among the compounds under the July 2026 PCAC 503A review — that process concerns bulk substances for compounding, a different regulatory track. The approved product has a defined label and manufacturing standards; compounded or off-label sourced versions fall outside that framework. Track current status →
Where to Source
Source research-grade Tesamorelin
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source Tesamorelin.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
Yes. It is approved as Egrifta for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, supported by Phase 3 randomized trials. That approval is specific to that indication — it does not extend to general fat loss or anti-aging use.
All three are GHRH analogs that raise the body’s own growth hormone. Tesamorelin stands apart because it has large Phase 3 trials and an FDA approval behind it, whereas sermorelin and CJC-1295 are used mostly on the strength of mechanism and smaller data.
In its studied population — people with HIV-associated lipodystrophy — yes: trials showed roughly 15–18% reductions in visceral fat versus placebo. The effect reverses after stopping, and it has not been formally tested for belly fat in otherwise-healthy adults.
No. That review dealt with bulk substances used in 503A compounding. Tesamorelin is already an FDA-approved drug, so it sat outside that process entirely.
Compare Tesamorelin